We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Ironwood Pharmaceuticals Inc | NASDAQ:IRWD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.17 | -2.43% | 6.83 | 6.83 | 6.84 | 7.04 | 6.805 | 7.01 | 590,390 | 16:36:30 |
From May 2023 to May 2024
By Sabela Ojea
Ironwood Pharmaceuticals said Monday that the U.S. Food and Drug Administration has granted approval to its Linzess treatment for pediatric patients with functional constipation.
The pharmaceutical company said Linzess has been approved for patients aged six to 17 years-old following the results of a large, multicenter, double-blind, phase 3 study.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
June 12, 2023 16:39 ET (20:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Ironwood Pharmaceuticals Chart |
1 Month Ironwood Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
